BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1088 related articles for article (PubMed ID: 10404792)

  • 21. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
    Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K
    Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma.
    Saab G; Driedger AA; Pavlosky W; McDonald T; Wong CY; Yoo J; Urbain JL
    Thyroid; 2006 Mar; 16(3):267-72. PubMed ID: 16571089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
    Ong SC; Ng DC; Sundram FX
    Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.
    Helal BO; Merlet P; Toubert ME; Franc B; Schvartz C; Gauthier-Koelesnikov H; Prigent A; Syrota A
    J Nucl Med; 2001 Oct; 42(10):1464-9. PubMed ID: 11585858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan.
    Kunawudhi A; Pak-art R; Keelawat S; Tepmongkol S
    Clin Nucl Med; 2012 Jun; 37(6):561-7. PubMed ID: 22614187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
    Kingpetch K; Pipatrattana R; Tepmongkol S; Sirisalipoch S; Chaiwatanarat T
    J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
    Schlüter B; Bohuslavizki KH; Beyer W; Plotkin M; Buchert R; Clausen M
    J Nucl Med; 2001 Jan; 42(1):71-6. PubMed ID: 11197983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
    Alnafisi NS; Driedger AA; Coates G; Moote DJ; Raphael SJ
    J Nucl Med; 2000 Jun; 41(6):1010-5. PubMed ID: 10855626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
    Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
    Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
    J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
    Wang W; Larson SM; Tuttle RM; Kalaigian H; Kolbert K; Sonenberg M; Robbins RJ
    Thyroid; 2001 Dec; 11(12):1169-75. PubMed ID: 12186505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diagnostic accuracy of 18F-FDG PET in residual or recurrent differentiated thyroid carcinoma with high thyroglobulin and negative 131-I whole-body scan].
    Cabrera Martín MN; Pasamontes Pingarrón JA; Carreras Delgado JL; Lapeña Gutiérrez L; Delgado Bolton RC; Bittini Copano A; Pérez Castejón MJ; Fernández Pérez C
    Rev Esp Med Nucl; 2007; 26(5):263-9. PubMed ID: 17910834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer.
    Iwano S; Kato K; Ito S; Tsuchiya K; Naganawa S
    Ann Nucl Med; 2012 Apr; 26(3):207-13. PubMed ID: 22160654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
    Shammas A; Degirmenci B; Mountz JM; McCook BM; Branstetter B; Bencherif B; Joyce JM; Carty SE; Kuffner HA; Avril N
    J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan].
    Sanz Viedma S; Borrego Dorado I; Rodríguez Rodríguez JR; Navarro González E; Vázquez Albertino R; Fernández López R; Agudo Martínez A
    Rev Esp Med Nucl; 2011; 30(2):77-82. PubMed ID: 21334773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
    Ruiz Franco-Baux JV; Borrego Dorado I; Gómez Camarero P; Rodríguez Rodríguez JR; Vázquez Albertino RJ; Navarro González E; Astorga Jiménez R
    Rev Esp Med Nucl; 2005; 24(1):5-13. PubMed ID: 15701340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level.
    Bertagna F; Bosio G; Biasiotto G; Rodella C; Puta E; Gabanelli S; Lucchini S; Merli G; Savelli G; Giubbini R; Rosenbaum J; Alavi A
    Clin Nucl Med; 2009 Nov; 34(11):756-61. PubMed ID: 19851169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18-fluorodeoxyglucose positron emission tomography in the early diagnostic workup of differentiated thyroid cancer patients with a negative post-therapeutic iodine scan and detectable thyroglobulin.
    van Dijk D; Plukker JT; Phan HT; Muller Kobold AC; van der Horst-Schrivers AN; Jansen L; Sluiter WJ; Brouwers AH; Links TP
    Thyroid; 2013 Aug; 23(8):1003-9. PubMed ID: 23517405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.